AsclepiX Therapeutics
PrivateLast Round
Series A
Extension
Jul 26, 2023
Total Funding Raised
$61.2M
Company Overview
AsclepiX Therapeutics operates in Healthcare & Life Sciences and is based in Baltimore, Maryland. Its latest recorded funding round was a Series A Extension round in July 2023.
AsclepiX Therapeutics is a biopharmaceutical company that develops novel peptide therapeutics for the treatment of retinal diseases and cancer using computational biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AsclepiX Therapeutics Comparables
Compare AsclepiX Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NEORTESBIO Inc. | 78% | |
| Allegro Ophthalmics | 77% | |
| Unity Biotechnology | 76% |
For institutional investors. Book with your work email.
AsclepiX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 26, 2023 | ||||
| Series A | Jun 24, 2020 | ||||
| Convertible Debt | Nov 13, 2018 | ||||
| Grant | Nov 12, 2018 | ||||
| Convertible Debt | Jul 22, 2016 |
For institutional investors. Book with your work email.
AsclepiX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hibiscus BioVentures | Series A Extension |
| National Cancer Institute | Grant |
| National Eye Institute (NIH) | Grant |
| Barer & Son Capital | Series A, Convertible Debt |
| Perceptive Advisors | Series A, Series A Extension |
| Research to Prevent Blindness | Grant |
| NIH RADx | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2023
$10M round led by Perceptive Advisors.
- Nov 13, 2018
$5M raised with Barer & Son Capital leading.
For institutional investors. Book with your work email.
AsclepiX Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AsclepiX Therapeutics's valuation, stock price, and market status.
Is AsclepiX Therapeutics a public or private company?
AsclepiX Therapeutics is a private company.
What is the current stock price of AsclepiX Therapeutics?
AsclepiX Therapeutics is a private company, so its shares have no public market price. Caplight tracks AsclepiX Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AsclepiX Therapeutics worth (valuation)?
Valuation information for AsclepiX Therapeutics is not publicly available.
Can I buy AsclepiX Therapeutics stock?
AsclepiX Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AsclepiX Therapeutics's last funding round?
AsclepiX Therapeutics's most recent funding round was Series A Extension on July 26, 2023.
Who are the main investors in AsclepiX Therapeutics?
Key investors in AsclepiX Therapeutics include Barer & Son Capital, Perceptive Advisors, Xontogeny, TEDCO.
Will AsclepiX Therapeutics IPO soon?
No public IPO plans have been announced for AsclepiX Therapeutics.
How can I track AsclepiX Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in AsclepiX Therapeutics's shares on secondary markets.